Regulation of Autophagy in Chronic Lymphocytic Leukemia: The Role of Histone Deacetylase Inhibitors

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    1 Citation (Scopus)


    Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5-positive B lymphocytes in the blood and lymphoid organs. Despite major advances in treatment regimens, this malignancy remains incurable. The emergence of resistance to chemotherapy is a major reason for the treatment failure and relapse. Tumor cells can escape death through activation of autophagy, an important obstacle for successful anticancer therapy. On the other hand, induction of autophagy by anticancer agents may in some instances promote cell death. In this chapter, we review the role of autophagy in CLL and the modulation of this process by genetic manipulation and pharmacological agents, and its outcome regarding cell viability. In particular, we analyze the major factors that determine the level of basal autophagy and provide evidence that this process is active in CLL. We, then, discuss the current knowledge about the regulation of autophagy in CLL, showing the potential clinical interest of histone deacetylase inhibitors.

    Original languageEnglish
    Title of host publicationAutophagy
    Subtitle of host publicationCancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging Volume 9: Human Diseases and Autophagosome
    Number of pages20
    ISBN (Electronic)9780128029367
    ISBN (Print)9780128029510
    Publication statusPublished - 1 Jan 2016

    Publication series

    NameHuman Diseases and Autophagosome


    • Chronic lymphocytic leukemia
    • anticancer therapy
    • autophagy suppressors
    • basal autophagy
    • histone deacetylase inhibitors


    Dive into the research topics of 'Regulation of Autophagy in Chronic Lymphocytic Leukemia: The Role of Histone Deacetylase Inhibitors'. Together they form a unique fingerprint.

    Cite this